BR112020014594A8 - Composições de diagnóstico para imageamento pet, método para fabricar composição de diagnóstico e seu uso em diagnóstico - Google Patents

Composições de diagnóstico para imageamento pet, método para fabricar composição de diagnóstico e seu uso em diagnóstico

Info

Publication number
BR112020014594A8
BR112020014594A8 BR112020014594A BR112020014594A BR112020014594A8 BR 112020014594 A8 BR112020014594 A8 BR 112020014594A8 BR 112020014594 A BR112020014594 A BR 112020014594A BR 112020014594 A BR112020014594 A BR 112020014594A BR 112020014594 A8 BR112020014594 A8 BR 112020014594A8
Authority
BR
Brazil
Prior art keywords
diagnostic compositions
diagnosis
pet imaging
manufacturing
diagnostic composition
Prior art date
Application number
BR112020014594A
Other languages
English (en)
Other versions
BR112020014594A2 (pt
Inventor
Castillo Melean Johnny
Betzel Thomas
Berndt Mathias
Schieferstein Hanno
Kroth Heiko
Molette Jérôme
Darmency Vincent
Gabellieri Emanuele
Original Assignee
Ac Immune Sa
Life Molecular Imaging Sa
Life Molecular Imaging Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa, Life Molecular Imaging Sa, Life Molecular Imaging Ltd filed Critical Ac Immune Sa
Publication of BR112020014594A2 publication Critical patent/BR112020014594A2/pt
Publication of BR112020014594A8 publication Critical patent/BR112020014594A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Polymerisation Methods In General (AREA)

Abstract

A presente invenção se refere a uma composição de diagnóstico compreendendo: a. um composto de Fórmula I, b. etanol, c. água, e d. um ácido hidroxicarboxílico, um sal de um ácido hidroxicarboxílico ou uma mistura dos mesmos. A composição de diagnóstico pode ser usada na detecção seletiva de distúrbios e anormalidades associados com agregados de Tau, tais como doença de Alzheimer (AD) e outras tauopatias, por exemplo, usando Tomografia por Emissão de Pósitrons (PET). A presente invenção também se refere a um método de preparar a composição de diagnóstico reivindicada.
BR112020014594A 2018-01-24 2019-01-22 Composições de diagnóstico para imageamento pet, método para fabricar composição de diagnóstico e seu uso em diagnóstico BR112020014594A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18153327.4 2018-01-24
EP18153327 2018-01-24
PCT/EP2019/051497 WO2019145293A1 (en) 2018-01-24 2019-01-22 Diagnostic compositions for pet imaging, a method for manufacturing the diagnostic composition and its use in diagnostics

Publications (2)

Publication Number Publication Date
BR112020014594A2 BR112020014594A2 (pt) 2020-12-01
BR112020014594A8 true BR112020014594A8 (pt) 2022-12-13

Family

ID=61192647

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020014594A BR112020014594A8 (pt) 2018-01-24 2019-01-22 Composições de diagnóstico para imageamento pet, método para fabricar composição de diagnóstico e seu uso em diagnóstico

Country Status (14)

Country Link
US (1) US20210047327A1 (pt)
EP (1) EP3743115A1 (pt)
JP (1) JP7260552B2 (pt)
KR (1) KR20200113241A (pt)
CN (1) CN111712265B (pt)
AU (1) AU2019210976B2 (pt)
BR (1) BR112020014594A8 (pt)
CA (1) CA3088232A1 (pt)
EA (1) EA202091766A1 (pt)
IL (1) IL275990B2 (pt)
MX (1) MX2020007487A (pt)
SG (1) SG11202006233XA (pt)
TW (1) TWI808119B (pt)
WO (1) WO2019145293A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2930259T3 (es) * 2018-01-24 2022-12-09 Ac Immune Sa Nuevo método para preparar un compuesto para imágenes
GB202005282D0 (en) 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
CN114835690B (zh) * 2022-07-04 2022-09-27 北京先通国际医药科技股份有限公司 含化合物i的液体组合物的制备方法、及在心肌灌注pet显像中的用途
CN114832118B (zh) * 2022-07-04 2022-09-27 北京先通国际医药科技股份有限公司 化合物i液体组合物、制备方法及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5258583B2 (ja) * 2007-02-13 2013-08-07 日本メジフィジックス株式会社 放射性画像診断剤の製造方法
KR20100077189A (ko) 2007-11-07 2010-07-07 지이 헬쓰케어 비브이 방사성약제의 안정화
WO2010078370A1 (en) * 2008-12-31 2010-07-08 Avid Radiopharmaceuticals, Inc. Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof
AU2010334929B2 (en) * 2009-12-23 2015-04-23 Life Molecular Imaging Limited Formulations suitable for pet imaging with hydrophobic pet agents
CN102939282B (zh) 2010-04-16 2015-12-02 Ac免疫有限公司 用于治疗与淀粉状蛋白或淀粉状蛋白样蛋白有关的疾病的化合物
ES2657121T3 (es) * 2013-10-08 2018-03-01 F. Hoffmann-La Roche Ag Derivados de diazacarbazol como ligandos tau-pet
US10662193B2 (en) * 2014-01-21 2020-05-26 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins
CN107198780A (zh) * 2016-03-18 2017-09-26 南京江原安迪科正电子研究发展有限公司 放射性药物组合物及其制备方法、应用
JP7059270B2 (ja) * 2016-07-22 2022-04-25 エーシー・イミューン・エス・アー タウタンパク質凝集体を画像化するための化合物
US10835624B2 (en) * 2016-07-22 2020-11-17 Ac Immune S.A. Compounds for imaging Tau protein aggregates
WO2018024642A1 (en) * 2016-08-02 2018-02-08 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
EP3743426A1 (en) * 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates
ES2930259T3 (es) * 2018-01-24 2022-12-09 Ac Immune Sa Nuevo método para preparar un compuesto para imágenes

Also Published As

Publication number Publication date
IL275990B1 (en) 2024-04-01
CA3088232A1 (en) 2019-08-01
CN111712265A (zh) 2020-09-25
EA202091766A1 (ru) 2021-02-18
BR112020014594A2 (pt) 2020-12-01
MX2020007487A (es) 2020-09-14
IL275990B2 (en) 2024-08-01
JP7260552B2 (ja) 2023-04-18
TW201932108A (zh) 2019-08-16
IL275990A (en) 2020-08-31
SG11202006233XA (en) 2020-08-28
CN111712265B (zh) 2024-02-09
JP2021512070A (ja) 2021-05-13
WO2019145293A1 (en) 2019-08-01
KR20200113241A (ko) 2020-10-06
EP3743115A1 (en) 2020-12-02
AU2019210976B2 (en) 2024-04-18
TWI808119B (zh) 2023-07-11
US20210047327A1 (en) 2021-02-18
AU2019210976A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
BR112020014594A8 (pt) Composições de diagnóstico para imageamento pet, método para fabricar composição de diagnóstico e seu uso em diagnóstico
BR112016028345A2 (pt) composto, composição farmacêutica, métodos para inibir agregação de tau em um mamífero e para avaliar depósitos de tau em um paciente, e, uso de um composto.
US20110224265A1 (en) Gel containing pirfenidone
BR112021022796A2 (pt) Inibidores de inflamassoma de nlrp3
BR112015025140A2 (pt) 2-fenilimidazo[1,2-a]pirimidinas como agentes de imagem
TR201904041T4 (tr) Protein agregasyonu ile bağlantılı hastalıklarda ve/veya nörodejeneratif hastalıklarda rol oynayan proteinlerin agregasyonunu inhibe etmeye yönelik ilaçlar.
BRPI0412986A (pt) composto, método para o diagnóstico ou formação de imagem in vivo de uma doença ou condição associadas com a angiogênese, formulação radiofarmacêutica, método para a preparação de um composto, e, kit para a preparação de um peptìdeo radiofluorado
BR112018007811A2 (pt) compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer
SI2945620T1 (en) Nitroxyl donors with improved therapeutic index
BR112019016291A2 (pt) novo composto heterocíclico, seu método de preparação e composição farmacêutica compreendendo o mesmo
BR112019000946A8 (pt) Compostos para imagiologia dos agregados da proteína tau
BR112016002651A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, combinação, formulação farmacêutica, métodos para exterminar uma micobactéria e/ou inibir a replicação das micobactérias, e para tratar uma infecção e uma doença, e, uso de um composto
MX346101B (es) Sonda de formacion de imagen de tau.
BRPI0610205A2 (pt) piperidinas 3,4-substituìdas como inibidores da renina
BRPI0917147B8 (pt) composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto
BR112017001093A2 (pt) formulação aquosa compreendendo paracetamol e ibuprofeno
EA202091767A1 (ru) Новый способ получения визуализирующего соединения
BR112022000782A2 (pt) Composto, composição farmacêutica, processo para preparar um composto, composto intermediário, e, uso de um composto, ou de um sal farmaceuticamente aceitável ou solvato do mesmo, ou de uma composição farmacêutica
ECSP19044591A (es) Amidas aromáticas de ácido carboxílico como antagonistas del receptor b1 de la bradiquinina
CN103479527B (zh) 麝香含漱液
Gabriël et al. A survey on anthelmintic resistance in nematode parasites of sheep in Lusaka, Zambia
Rossi et al. Anti-ganglioside specific auto-antibodies in ganglia of PDD-affected parrots
BR112022010498A2 (pt) Cocristal de cetoprofeno e sua preparação, composições farmacêuticas compreendendo o mesmo e seu uso
Patel et al. Prevalence of dermatophytes in skin, hair and nail at tertiary care hospital at Ahmdeabad
RU2367426C1 (ru) Средство для лечения кожи воспалительной и аллергической этиологии у кошек и собак "стоп-зуд-1"

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: AC IMMUNE SA. (CH) ; LIFE MOLECULAR IMAGING LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: AC IMMUNE SA. (CH) ; LIFE MOLECULAR IMAGING LIMITED (GB)